The Efficacy and Tolerability of Seroquel XR Combined with a Selective Serotonin Re-Uptake Inhibitor versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder with Psychotic Features
Have you been feeling down or depressed lately? If so, do you have unusual experiences where it seems that people are out to give you a hard time or to hurt you; do you hear, see, feel, smell, or taste things that other people do not experience?
If you have these symptoms, you may be suffering from a specific type of Major Depressive Disorder and may be eligible to participate in a treatment study at Massachusetts General Hospital. The purpose of this research study is to examine the effectiveness and safety of Seroquel when it is taken alone, compared to when it is taken in addition to an antidepressant, in the treatment of Major Depressive Disorder with Psychotic Features. You may be eligible if you are between the ages of 18-85 years.
The study involves 9 weekly visits to the DCRP. All subjects in this study will receive active treatment, and will be assigned by chance, like the flip of a coin, to take either Seroquel alone, or the combination of Seroquel and an antidepressant (Sertraline, Citalopram or Escitalopram).
If interested, please call Rita at 617-724-9142 or rseabrook@partners.org.
All inquiries will be completely confidential.
We initiate new studies regularly, so please contact us for additional information.